AREG and prostate carcinoma: Again, studies in other tumor entities revealed an ambiguous picture, with the HDAC1-, HDAC3- and HDAC6-specific inhibitor SN30028 leading to a persistent downregulation of amphiregulin in the prostate carcinoma cell line PC3 [39].